Three Hidden Gems the Market Is Sleeping On: CAR, Cannabis Micro-Caps, and the Psychedelic FDA Rocket

While the internet collectively lost its mind over $INTC hitting dot-com-era highs, a Bloomberg podcast quietly dropped something spicy: $CAR (Avis Budget Group) ripped from ~$100 to ~$713 on what analysts are calling a classic short-squeeze meme dynamic — earnings still pending. That kind of asymmetric setup, where short interest is sky-high and a single catalyst can cause violent covering, is exactly the kind of thing that makes your portfolio interesting. The crowd missed it. Don't be the crowd.

Then there's the cannabis angle. CB1 Capital Management called Trump's rescheduling move the biggest cannabis industry news since Nixon — and the real kicker is the Treasury's surprise signal on Section 280E back-tax relief for medical operators. That's existential cost removal for small cannabis operators drowning in tax bills. The ALJ hearing on June 28th is your date to circle. Stocks like $TLRY (Tilray Brands) stand to benefit directly as institutional custody barriers start to fall.

Finally, the FDA fast-tracking psychedelic drug research via priority vouchers — with review times slashed from a year to a few months — is handing a rocket to clinical-stage players like $CMPO... wait, scratch that. $MNMD (Mind Medicine) is a NASDAQ-listed micro-cap psychedelic therapeutics company right in the crosshairs of this PTSD and depression treatment wave, and it's still trading like nobody noticed the executive order. Consider that your hint.

The biggest gains rarely come from the stocks everyone is already talking about — they come from the ones you explain to your friends before they go up.